Nothing Special   »   [go: up one dir, main page]

HK1246322A1 - 長效的ctp修飾的多肽製備方法 - Google Patents

長效的ctp修飾的多肽製備方法

Info

Publication number
HK1246322A1
HK1246322A1 HK18105854.4A HK18105854A HK1246322A1 HK 1246322 A1 HK1246322 A1 HK 1246322A1 HK 18105854 A HK18105854 A HK 18105854A HK 1246322 A1 HK1246322 A1 HK 1246322A1
Authority
HK
Hong Kong
Prior art keywords
methods
long acting
modified polypeptides
producing long
ctp
Prior art date
Application number
HK18105854.4A
Other languages
English (en)
Inventor
Oren Hershkovitz
Laura Moschcovich
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of HK1246322A1 publication Critical patent/HK1246322A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0633—Workflow analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
    • G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0201—Market modelling; Market analysis; Collecting market data
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Human Resources & Organizations (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Strategic Management (AREA)
  • Biotechnology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Economics (AREA)
  • Development Economics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Educational Administration (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Business, Economics & Management (AREA)
  • Game Theory and Decision Science (AREA)
  • Marketing (AREA)
  • Reproductive Health (AREA)
  • Operations Research (AREA)
  • Finance (AREA)
  • Accounting & Taxation (AREA)
  • Tourism & Hospitality (AREA)
HK18105854.4A 2014-12-10 2018-05-07 長效的ctp修飾的多肽製備方法 HK1246322A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462090116P 2014-12-10 2014-12-10
US201462090124P 2014-12-10 2014-12-10
US201462090104P 2014-12-10 2014-12-10
PCT/IL2015/051197 WO2016092550A2 (en) 2014-12-10 2015-12-10 Methods of producing long acting ctp-modified polypeptides

Publications (1)

Publication Number Publication Date
HK1246322A1 true HK1246322A1 (zh) 2018-09-07

Family

ID=56106835

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103050.1A HK1243444A1 (zh) 2014-12-10 2018-03-02 長效的ctp修飾的生長激素多肽的製備方法
HK18105854.4A HK1246322A1 (zh) 2014-12-10 2018-05-07 長效的ctp修飾的多肽製備方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18103050.1A HK1243444A1 (zh) 2014-12-10 2018-03-02 長效的ctp修飾的生長激素多肽的製備方法

Country Status (23)

Country Link
US (3) US20160168588A1 (zh)
EP (4) EP3230309B1 (zh)
KR (3) KR102527180B1 (zh)
CN (1) CN107438623B (zh)
AU (2) AU2015358890B2 (zh)
CO (1) CO2017006870A2 (zh)
EA (1) EA201791275A1 (zh)
ES (1) ES2943359T3 (zh)
HK (2) HK1243444A1 (zh)
HR (1) HRP20230405T8 (zh)
IL (2) IL252778B (zh)
MX (2) MX2017007634A (zh)
NO (1) NO2023036I1 (zh)
NZ (2) NZ767924A (zh)
PE (1) PE20171380A1 (zh)
PH (1) PH12017501089A1 (zh)
PL (1) PL3230309T3 (zh)
RU (2) RU2021103436A (zh)
SG (1) SG11201704706RA (zh)
SI (1) SI3230309T1 (zh)
TW (2) TW202231657A (zh)
WO (2) WO2016092549A1 (zh)
ZA (1) ZA201704595B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EA201791275A1 (ru) 2014-12-10 2017-12-29 Опко Байолоджикс Лтд. Способы получения ctp-модифицированных полипептидов длительного действия
KR102662956B1 (ko) 2015-06-19 2024-05-03 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법
AU2017296352A1 (en) * 2016-07-11 2019-02-21 Opko Biologics Ltd. Long-acting coagulation factor VII and methods of producing same
RU2652884C1 (ru) * 2016-11-25 2018-05-03 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2021005604A1 (en) * 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
EP4308151A1 (en) * 2021-03-19 2024-01-24 Pfizer Inc. Methods of administering long-acting growth hormone polypeptides
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE68917883T2 (de) 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
DE69011177T2 (de) * 1989-04-28 1994-12-08 Miles Inc Grossfermenter-Inokulation mit gefrorenen Zellen.
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
NZ265529A (en) * 1993-04-20 1998-01-26 Univ Washington Peptide/protein modified with insertion of complete or partial carboxy terminal peptide unit into a non critical region
ATE184798T1 (de) * 1994-06-17 1999-10-15 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
CN1847265A (zh) * 2005-04-15 2006-10-18 上海市计划生育科学研究所 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US20140113860A1 (en) * 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US9249407B2 (en) * 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
NZ608943A (en) * 2010-10-11 2015-04-24 Abbvie Bahamas Ltd Processes for purification of proteins
SG11201404836QA (en) 2012-02-14 2014-12-30 Opko Biolog Ltd Long-acting coagulation factors and methods of producing same
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
AU2013250711A1 (en) * 2012-04-19 2014-11-27 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
SG11201503879QA (en) * 2012-11-20 2015-06-29 Opko Biolog Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US11045523B2 (en) * 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EA201791275A1 (ru) 2014-12-10 2017-12-29 Опко Байолоджикс Лтд. Способы получения ctp-модифицированных полипептидов длительного действия
KR102662956B1 (ko) * 2015-06-19 2024-05-03 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법

Also Published As

Publication number Publication date
NZ733113A (en) 2020-09-25
HRP20230405T1 (hr) 2023-09-01
RU2743295C2 (ru) 2021-02-16
RU2017123789A3 (zh) 2019-01-10
IL252778A0 (en) 2017-08-31
WO2016092549A1 (en) 2016-06-16
EP4212546A1 (en) 2023-07-19
RU2021103436A (ru) 2021-02-25
WO2016092550A3 (en) 2016-08-04
US20210371487A1 (en) 2021-12-02
CN107438623B (zh) 2023-07-14
NO2023036I1 (no) 2023-09-28
CN107438623A (zh) 2017-12-05
US20160168588A1 (en) 2016-06-16
IL252778B (en) 2021-09-30
ZA201704595B (en) 2019-06-26
TW201638105A (zh) 2016-11-01
AU2019203609A1 (en) 2019-06-13
TWI746427B (zh) 2021-11-21
KR102527180B1 (ko) 2023-04-27
EP3240564A4 (en) 2018-05-30
EP3240564A2 (en) 2017-11-08
PL3230309T3 (pl) 2023-08-28
HK1243444A1 (zh) 2018-07-13
EP3230309A1 (en) 2017-10-18
IL252788A0 (en) 2017-08-31
PE20171380A1 (es) 2017-09-15
MX2017007634A (es) 2017-08-28
CO2017006870A2 (es) 2018-01-05
TW202231657A (zh) 2022-08-16
ES2943359T3 (es) 2023-06-12
KR20170086664A (ko) 2017-07-26
WO2016092550A2 (en) 2016-06-16
KR102164352B1 (ko) 2020-10-13
EP4253407A3 (en) 2023-12-06
HRP20230405T8 (hr) 2023-09-29
EP3230309B1 (en) 2023-03-29
AU2019203609B2 (en) 2021-02-25
NZ767924A (en) 2024-07-05
SI3230309T1 (sl) 2023-08-31
AU2015358890A1 (en) 2017-07-20
KR20200118505A (ko) 2020-10-15
IL252788B (en) 2021-09-30
RU2017123789A (ru) 2019-01-10
MX2017007635A (es) 2017-09-11
US20180111974A1 (en) 2018-04-26
AU2015358890B2 (en) 2019-06-13
EP4253407A2 (en) 2023-10-04
BR112017012498A2 (pt) 2018-07-31
PH12017501089A1 (en) 2017-10-18
KR20220058564A (ko) 2022-05-09
SG11201704706RA (en) 2017-07-28
EA201791275A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
HK1246322A1 (zh) 長效的ctp修飾的多肽製備方法
GB201413086D0 (en) Methods
GB2511010B (en) Method of producing thiamethoxam
GB2522719B (en) Method of manufacture
HUP1400114A2 (en) Method for the production of peptides
SG11201608857WA (en) Template-assisted production of porous materials
IL252086A0 (en) New methods
GB201506074D0 (en) Object production
EP3180296A4 (en) Methods of producing alkylfurans
GB201408745D0 (en) Methods
IL252712A0 (en) Method for protein production
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
GB2522716B (en) Method of manufacture
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
GB2532451B (en) Object production
GB2522904B (en) Method of making an airdam
GB201415685D0 (en) Methods
HK1232253A1 (zh) 生產多肽的方法
GB201509143D0 (en) Methods of characterizing polypeptides
GB201416951D0 (en) Method of synthesis
GB201406303D0 (en) Production of objects
GB201406777D0 (en) Production of drops
GB201405158D0 (en) Theory of european law
GB201414122D0 (en) Methods
GB201407184D0 (en) Object production